New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

FUTURE ONCOLOGY
Volume 4 #12 April 1999
State-of-the-Art in the Management of Cancer

KIDNEY CANCER-PART III
NOVEL MANAGEMENT APPROACHES IN DEVELOPMENT

Mechanisms in Renal Cell Carcinoma

Drug Resistance

Angiogenesis

  • Thalidomide
  • TNP-470

Overexpression of the Epidermic Growth Factor Receptor (EGFr)

  • C225
  • MDX-447

Overproduction of IL-6

  • Regeneron Pharmaceuticals

Novel Chemotherapeutics

9-aminocamptothecin (9-AC)

Amino-substituted Flavone

Acylfulvenes (6-HMAF)

Arsenic Trioxide (As2O3)

CI-994

CT-2584Diethylnorspermine (DENSPM)

GD0039

LY355703

Maxamine

Onconase

Platar

Troxacitabine

UFT

Systemically-administered Immunomodulators

Interferon a (IFN-a )

  • Pegasys

Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)

Recombinant Human Erythropoietin (rHuEPO)Interleukin-12 (IL-12)

Interferon g (IFN-g )

Tumor Necrosis Factor

  • Colloidal gold-bound TNF

Transfer of Cytokine Genes

Genes Expressing GM-CSF

Genes Expressing IL-12

DISC-HSV Vector

Leuvectin

Monoclonal Antibodies

Anti-G250 Mab

HER2/neu

  • MDX-210
  • MAb-IL-12 Fusion Protein

Vitaxin


HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887